Day: August 9, 2021

NEWMARKET, Ontario, Aug. 09, 2021 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX: ABSSF) (the “Company” or “AirBoss”) announced today that Company management will present at Canaccord Genuity’s 41st Annual Growth Conference on Thursday, August 12, 2021. The conference is being held virtually this year and interested parties can listen to a live webcast of management’s presentation. The presentation will be archived for 90 days. CANACCORD GENUITY GROWTH CONFERENCE WEBCAST DETAILS:DATE:TIME:WEBCAST LINK: Thursday, August 12, 20218:00 am EThttps://wsw.com/webcast/canaccord60/bos.to/2764212Please connect approximately 5 to 10 minutes prior to the beginning of the webcast to register. Investor Contact: Tim Foran at Tim.Foran@airboss.com or 416-986-8515. Media Contact: media@airboss.com AirBoss of America Corp. AirBoss...

PAOLI, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) — Malvern Bancorp, Inc. (NASDAQ: MLVF) (the “Company”), the parent company of Malvern Bank, National Association (the “Bank”), today reported operating results for the third fiscal quarter ended June 30, 2021. Net income amounted to $1.6 million, or $0.21 per fully diluted common share, compared with net income of $1.5 million, or $0.19 per fully diluted common share, for the quarter ended June 30, 2020. The increases in net income and diluted earnings per share from the third quarter of 2020 were primarily due to an increase in net interest income and other income. Annualized return on average assets (“ROAA”) was 0.53 percent for the quarter ended June 30, 2021, compared to 0.47 percent for the quarter ended June 30, 2020, and annualized return on average equity (“ROAE”) was 4.35 percent...

CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. Second quarter CAPLYTA total prescriptions (TRx) increased 22% versus the previous quarter. Total revenues for the second quarter were $20.0 million. CAPLYTA achieved net product revenues of $19.0 million for the second quarter. Patient enrollment in Study ‘501, a Phase 3 clinical trial evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD), has commenced. NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced...

SANTA CLARA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2021. Recent HighlightsRecognized revenue of $55.9 million for the second quarter of 2021, representing an increase of 444% from the same period in 2020 Granted approval for a Transitional Pass-Through (TPT) payment for Shockwave C2 Coronary IVL device, which became effective July 1, 2021 for procedures in the outpatient setting Featured in three publications in the Journal of the American College of Cardiology: Cardiovascular Interventions (JACC CI), which supported the clinical safety and efficacy of Shockwave Intravascular Lithotripsy Granted...

Generates Increased Sales, Volume Growth and Strong Operating Results SPRINGDALE, Ark., Aug. 09, 2021 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, today reported the following results:(in millions, except per share data) Third Quarter   Nine Months Ended  2021   2020 1   2021   2020 1Sales $ 12,478      $ 10,022      $ 34,238      $ 31,725   Operating Income 1,062      773      2,487      2,046                  Net Income 753      526      1,702      1,414   Less: Net Income Attributable to Noncontrolling Interests 4      —      10      7   Net Income Attributable to Tyson $ 749      $ 526      $ 1,692      $ 1,407                  Net...

GREENWICH, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (the “Company”) (Nasdaq GS: OXLC, OXLCM, OXLCP and OXLCL) today announced that it plans to offer shares of its newly designated Series 2029 Term Preferred Shares (the “Preferred Stock”) in an underwritten public offering. The public offering price and other terms of the Preferred Stock are to be determined by negotiations between the Company and the underwriters. The Company also plans to grant the underwriters a 30-day option to purchase additional shares of Preferred Stock on the same terms and conditions to cover over-allotments, if any.  Ladenburg Thalmann & Co. Inc., B. Riley Securities, Inc., InspereX LLC and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering and Compass Point Research & Trading,...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) — Asante Gold Corporation (CSE:ASE/ FRANKFURT:1A9/U.S.OTC:ASGOF) (“Asante” or the “Company”) announces that the Company has granted 6.9 million incentive stock options at $0.75 per share for a term of 5 years to directors, consultants and employees. “Douglas R. MacQuarrie”President and CEO About Asante Gold Corporation Asante is a pure gold exploration and development company with a high-quality portfolio of projects in Ghana, Africa’s largest and safest gold producer. Asante is focused on developing high margin gold projects including the Bibiani and Kubi Gold mines located on the prolific Bibiani and Ashanti Gold Belts. Asante has an experienced and skilled...

Figure 1Plan view of the PGP site showing the location of the drill pads in relation to the mill building and existing resources. Results from drill pad NL-W01 were previously reported.VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) is pleased to announce additional high-grade results in step-out and exploration drillholes from the ongoing 25,000m drill program at the Company’s Premier Gold Project (“PGP”). Before moving to higher elevations, drilling this season to date has focused on the area to the northwest of the Premier/Northern Light zones. High-grade gold was intercepted from multiple drill locations and at various depths, expanding previously identified areas of mineralization and adding new zones. Highlights from the...

Executive team to update investors via webinar on recent business developments and the acquisition of Xcite Interactive LOS ANGELES, Aug. 09, 2021 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) announced today that it will host an investor webinar on Monday, August 16, 2021, to provide an update on the business. The webinar will begin at 2:00 p.m. PT (5:00 p.m. ET). Investors will be able to access the event in the investor relations section of the company’s website at https://ir.versussystems.com/. Versus Systems’ executive management team will discuss second quarter 2021 developments, details regarding the integration of Xcite Interactive, and the company’s strategies for growth and related milestones. Investors may register for the webinar here. Questions for the Q&A session may be sent...

MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet (neovascular) age-related macular degeneration (AMD). Following formal authorization from the regulatory agency Health Canada, patient enrollment in the two concurrent Phase 3 registrational clinical trials, ShORe (Study of OPT-302 in combination with Ranibizumab) and COAST (Combination OPT-302 with Aflibercept Study) can now begin in Canada. The goal of the two studies is to evaluate the benefits of the Company’s VEGF-C/D ‘trap’ inhibitor, OPT-302, for wet AMD in treatment-naïve...